ZEALAND PHARMA A/S shares fell 13% on Thursday after trial data showed nearly one in five patients quit late-stage survodutide trials due to gastrointestinal side effects. It is the second time this year that dropout concerns have hit the Denmark-based drugmaker. The obesity drug, developed in partnership with Boehringer Ingelheim, faces scrutiny over tolerability.
Zealand Pharma Shares Slide on Trial Dropouts
Zealand Pharma shares dropped after nearly one in five patients quit a late-stage survodutide trial due to side effects. The data raised fresh investor concerns regarding dropout rates for the obesity drug developed with Boehringer Ingelheim.
Xurve View
Insights:
Xurve View




